BlackRock Advisors’s Larimar Therapeutics LRMR Stock Holding History

BlackRock Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$31K	Hold	812	–	–	﹤0.01%	3365
2016 Q3	$32K	Buy	812 +14	+2%	+$636	﹤0.01%	3354
2016 Q2	$57K	Buy	798 +132	+20%	+$10.4K	﹤0.01%	3194
2016 Q1	$53K	Buy	666 +61	+10%	+$4.82K	﹤0.01%	3149
2015 Q4	$46K	Sell	605 -16,389	-96%	-$2.63M	﹤0.01%	3230
2015 Q3	$6.52M	Buy	16,994 +44	+0.3%	+$19.8K	0.01%	987
2015 Q2	$7.04M	Buy	16,950 +484	+3%	+$202K	0.01%	873
2015 Q1	$7.83M	Buy	16,466 +16,245	+7,351%	+$7.71M	0.01%	861
2014 Q4	$82K	Hold	221	–	–	﹤0.01%	3138
2014 Q3	$52K	Buy	+221	New	+$50.1K	﹤0.01%	3257

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock Advisors's LRMR Position: Q4 2016 in Review

BlackRock Advisors held its Larimar Therapeutics (LRMR) position steady in Q4 2016 at 812 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #3365.

BlackRock Advisors first reported a position in LRMR in Q3 2014 and has held it in 10 quarters since. The position peaked at $7.83M in Q1 2015. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

BlackRock Advisors held 812 shares of Larimar Therapeutics worth $31K as of Q4 2016.
BlackRock Advisors left its Larimar Therapeutics share count unchanged in Q4 2016.
Larimar Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3365 holding.
BlackRock Advisors first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 10 quarters since.
BlackRock Advisors's Larimar Therapeutics position peaked at $7.83M in Q1 2015.
81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.